Suchergebnisse
Suchergebnisse:
Cardiogenic Shock: the primary circulatory shock in ICUs with a mortality rate over 70%. Triggered by acute myocardial injuries like heart attacks, it leads to severe left-ventricular dysfunction.
- About Us
4TEEN4 Pharmaceuticals is built on science, innovation, and...
- Theragnostics
Discover how 4TEEN4 Pharmaceuticals' innovation, Procizumab,...
- Biopharmapartners
Supported by. The project is funded by the European Social...
- Career
4TEEN4 Pharmaceuticals is built on science, innovation, and...
- News & Media
Today, 4TEEN4 Pharmaceuticals announces dosing of the first...
- Imprint / Impressum
Official imprint of 4TEEN4 Pharmaceuticals GmbH, providing...
- About Us
4TEEN4 Pharmaceuticals is built on science, innovation, and dedication, where you can use your enthusiasm in changing patients’ lives and creating impact. We are a fast-growing, small-medium enterprise (SME) that grants our employees the ability to grow and shape their career pathways by developing an agile approach.
Discover how 4TEEN4 Pharmaceuticals' innovation, Procizumab, a humanized monoclonal antibody targeting DPP3, offers new hope by improving outcomes and guiding therapy escalation in acute critical disease entities. Learn about the promising implications of DPP3 for monitoring acute coronary syndrome and its integration into clinical practice ...
Der Fokus der 4TEEN4 Pharmaceuticals sind Patienten mit Erkrankungen, die mit massivem Zelltod und damit zusammenhängend einer unkontrollierten Freisetzung von Dipeptidylpeptidase 3 (DPP3) in die Blutbahn verbunden sind.
Das biopharmazeutische Unternehmen 4TEEN4 Pharmaceuticals GmbH entwickelt Procizumab, einen humanisierten, gegen die humane Dipeptidyl-Peptidase 3 (DPP3) gerichteten Antikörper zur Behandlung akuter Herz-Kreislauf-Erkrankungen. 4TEEN4 lizenzierte die diagnostischen Rechte für DPP3 als akutmedizinischen Biomarker für ...
4TEEN4 Pharmaceuticals Arzneimittelherstellung Hennigsdorf, Berlin 657 Follower:innen Improving critical care management
Das biopharmazeutische Unternehmen 4TEEN4 Pharmaceuticals GmbH entwickelt Procizumab, einen humanisierten, gegen die humane Dipeptidyl-Peptidase 3 (DPP3) gerichteten Antikörper zur Behandlung ...